Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA Lung-201: Pumitamig vs Durvalumab After Chemoradiation in Unresectable Stage III NSCLC
jRCT2051260046Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of pumitamig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival by blinded independent central review. Started May 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051260046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260046.